CN102160664A - 儿童营养饮料 - Google Patents
儿童营养饮料 Download PDFInfo
- Publication number
- CN102160664A CN102160664A CN2011100492178A CN201110049217A CN102160664A CN 102160664 A CN102160664 A CN 102160664A CN 2011100492178 A CN2011100492178 A CN 2011100492178A CN 201110049217 A CN201110049217 A CN 201110049217A CN 102160664 A CN102160664 A CN 102160664A
- Authority
- CN
- China
- Prior art keywords
- children
- kilograms
- theanine
- blood
- zinc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000008935 nutritious Nutrition 0.000 title abstract description 4
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims abstract description 74
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 72
- 229960003080 taurine Drugs 0.000 claims abstract description 36
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 28
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 28
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 28
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 28
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 28
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 28
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 28
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 28
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 28
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 28
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims abstract description 25
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 25
- 240000001008 Dimocarpus longan Species 0.000 claims abstract description 24
- 235000000235 Euphoria longan Nutrition 0.000 claims abstract description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000002994 raw material Substances 0.000 claims abstract description 18
- 235000015468 Lycium chinense Nutrition 0.000 claims abstract description 17
- 239000000047 product Substances 0.000 claims abstract description 16
- 239000000706 filtrate Substances 0.000 claims abstract description 13
- 239000000463 material Substances 0.000 claims abstract description 10
- 230000001954 sterilising effect Effects 0.000 claims abstract description 10
- DATAGRPVKZEWHA-UHFFFAOYSA-N L-gamma-glutamyl-n-ethylamine Natural products CCNC(=O)CCC(N)C(O)=O DATAGRPVKZEWHA-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229920001202 Inulin Polymers 0.000 claims abstract description 7
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 7
- 229940029339 inulin Drugs 0.000 claims abstract description 7
- 238000001914 filtration Methods 0.000 claims abstract description 6
- 238000003756 stirring Methods 0.000 claims abstract description 6
- 238000011049 filling Methods 0.000 claims abstract description 5
- 238000002156 mixing Methods 0.000 claims abstract description 5
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- DKKCQDROTDCQOR-UHFFFAOYSA-L Ferrous lactate Chemical compound [Fe+2].CC(O)C([O-])=O.CC(O)C([O-])=O DKKCQDROTDCQOR-UHFFFAOYSA-L 0.000 claims abstract description 3
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims abstract description 3
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims abstract description 3
- 235000011086 calcium lactate Nutrition 0.000 claims abstract description 3
- 235000013925 ferrous lactate Nutrition 0.000 claims abstract description 3
- 239000004225 ferrous lactate Substances 0.000 claims abstract description 3
- 229940037907 ferrous lactate Drugs 0.000 claims abstract description 3
- 235000011478 zinc gluconate Nutrition 0.000 claims abstract description 3
- 239000011670 zinc gluconate Substances 0.000 claims abstract description 3
- 229960000306 zinc gluconate Drugs 0.000 claims abstract description 3
- 240000000171 Crataegus monogyna Species 0.000 claims abstract 3
- 240000000950 Hippophae rhamnoides Species 0.000 claims abstract 3
- 238000000034 method Methods 0.000 claims description 17
- 230000008569 process Effects 0.000 claims description 16
- 244000241872 Lycium chinense Species 0.000 claims description 15
- 235000016709 nutrition Nutrition 0.000 claims description 13
- 230000035764 nutrition Effects 0.000 claims description 11
- 238000004659 sterilization and disinfection Methods 0.000 claims description 8
- 238000012360 testing method Methods 0.000 claims description 8
- 241000196324 Embryophyta Species 0.000 claims description 6
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 238000005516 engineering process Methods 0.000 claims description 4
- 238000012856 packing Methods 0.000 claims description 4
- 230000002787 reinforcement Effects 0.000 claims description 4
- 230000035622 drinking Effects 0.000 claims description 3
- 235000012054 meals Nutrition 0.000 claims description 3
- 238000013019 agitation Methods 0.000 claims 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract description 51
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract description 45
- 229910052725 zinc Inorganic materials 0.000 abstract description 43
- 239000011701 zinc Substances 0.000 abstract description 43
- 239000011575 calcium Substances 0.000 abstract description 42
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 40
- 229910052791 calcium Inorganic materials 0.000 abstract description 40
- 230000006870 function Effects 0.000 abstract description 37
- 210000004369 blood Anatomy 0.000 abstract description 36
- 239000008280 blood Substances 0.000 abstract description 36
- 229910052742 iron Inorganic materials 0.000 abstract description 25
- 229960003284 iron Drugs 0.000 abstract description 25
- 210000000952 spleen Anatomy 0.000 abstract description 24
- 230000015654 memory Effects 0.000 abstract description 21
- 230000036039 immunity Effects 0.000 abstract description 20
- 230000012010 growth Effects 0.000 abstract description 19
- 210000002784 stomach Anatomy 0.000 abstract description 11
- 230000029087 digestion Effects 0.000 abstract description 6
- 244000241838 Lycium barbarum Species 0.000 abstract description 5
- 235000015459 Lycium barbarum Nutrition 0.000 abstract description 5
- 230000004641 brain development Effects 0.000 abstract description 5
- 230000002708 enhancing effect Effects 0.000 abstract description 5
- 230000007958 sleep Effects 0.000 abstract description 5
- 238000002386 leaching Methods 0.000 abstract description 2
- 238000009835 boiling Methods 0.000 abstract 1
- 229960005069 calcium Drugs 0.000 abstract 1
- 229960002401 calcium lactate Drugs 0.000 abstract 1
- 239000001527 calcium lactate Substances 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 238000002844 melting Methods 0.000 abstract 1
- 230000008018 melting Effects 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 238000007789 sealing Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 66
- 235000016804 zinc Nutrition 0.000 description 42
- 241000699666 Mus <mouse, genus> Species 0.000 description 41
- 210000004185 liver Anatomy 0.000 description 30
- 229940026510 theanine Drugs 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 28
- 241001092040 Crataegus Species 0.000 description 25
- 210000004556 brain Anatomy 0.000 description 25
- 241000229143 Hippophae Species 0.000 description 24
- 230000002929 anti-fatigue Effects 0.000 description 18
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 16
- 238000011161 development Methods 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 239000000284 extract Substances 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 210000000988 bone and bone Anatomy 0.000 description 13
- 229940088598 enzyme Drugs 0.000 description 13
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 12
- 230000018109 developmental process Effects 0.000 description 12
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 12
- 229910052760 oxygen Inorganic materials 0.000 description 12
- 239000001301 oxygen Substances 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 208000007502 anemia Diseases 0.000 description 11
- 235000013361 beverage Nutrition 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 238000011160 research Methods 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 206010022971 Iron Deficiencies Diseases 0.000 description 10
- 239000000796 flavoring agent Substances 0.000 description 10
- 235000019634 flavors Nutrition 0.000 description 10
- 150000002632 lipids Chemical class 0.000 description 10
- 230000001681 protective effect Effects 0.000 description 10
- 230000028327 secretion Effects 0.000 description 10
- 108010054147 Hemoglobins Proteins 0.000 description 9
- 102000001554 Hemoglobins Human genes 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 229930003944 flavone Natural products 0.000 description 9
- 235000011949 flavones Nutrition 0.000 description 9
- 230000004060 metabolic process Effects 0.000 description 9
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 229930003268 Vitamin C Natural products 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 8
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 8
- 230000036737 immune function Effects 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 210000002569 neuron Anatomy 0.000 description 8
- 230000035790 physiological processes and functions Effects 0.000 description 8
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 8
- 235000019154 vitamin C Nutrition 0.000 description 8
- 239000011718 vitamin C Substances 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 230000000259 anti-tumor effect Effects 0.000 description 7
- 230000003078 antioxidant effect Effects 0.000 description 7
- 210000003792 cranial nerve Anatomy 0.000 description 7
- 210000001320 hippocampus Anatomy 0.000 description 7
- 230000001077 hypotensive effect Effects 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 235000015097 nutrients Nutrition 0.000 description 7
- 230000000242 pagocytic effect Effects 0.000 description 7
- 230000000144 pharmacologic effect Effects 0.000 description 7
- 208000001953 Hypotension Diseases 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 210000005013 brain tissue Anatomy 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 229960003638 dopamine Drugs 0.000 description 6
- 206010016256 fatigue Diseases 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 6
- 208000021822 hypotensive Diseases 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 230000004379 myopia Effects 0.000 description 6
- 208000001491 myopia Diseases 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- 230000001603 reducing effect Effects 0.000 description 6
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 5
- 230000002180 anti-stress Effects 0.000 description 5
- 206010003119 arrhythmia Diseases 0.000 description 5
- 229960003237 betaine Drugs 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000008468 bone growth Effects 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 150000002212 flavone derivatives Chemical class 0.000 description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 5
- 235000013922 glutamic acid Nutrition 0.000 description 5
- 239000004220 glutamic acid Substances 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 210000005229 liver cell Anatomy 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- -1 phosphate acid amides Chemical class 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 210000001541 thymus gland Anatomy 0.000 description 5
- 235000019155 vitamin A Nutrition 0.000 description 5
- 239000011719 vitamin A Substances 0.000 description 5
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 229920002527 Glycogen Polymers 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- 230000003712 anti-aging effect Effects 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 230000006793 arrhythmia Effects 0.000 description 4
- 230000037444 atrophy Effects 0.000 description 4
- 210000003710 cerebral cortex Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 150000002213 flavones Chemical class 0.000 description 4
- 229930182478 glucoside Natural products 0.000 description 4
- 150000008131 glucosides Chemical class 0.000 description 4
- 229960003180 glutathione Drugs 0.000 description 4
- 229940096919 glycogen Drugs 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 206010022437 insomnia Diseases 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 208000031225 myocardial ischemia Diseases 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000000630 rising effect Effects 0.000 description 4
- 230000014860 sensory perception of taste Effects 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 230000009182 swimming Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000011573 trace mineral Substances 0.000 description 4
- 235000013619 trace mineral Nutrition 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 3
- 201000006474 Brain Ischemia Diseases 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- 206010027439 Metal poisoning Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102000010909 Monoamine Oxidase Human genes 0.000 description 3
- 108010062431 Monoamine oxidase Proteins 0.000 description 3
- 229930003316 Vitamin D Natural products 0.000 description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000003266 anti-allergic effect Effects 0.000 description 3
- 230000000496 anti-anoxic effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000000941 bile Anatomy 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 230000014461 bone development Effects 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 230000007969 cellular immunity Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 201000006549 dyspepsia Diseases 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 231100000753 hepatic injury Toxicity 0.000 description 3
- 230000004727 humoral immunity Effects 0.000 description 3
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 208000008127 lead poisoning Diseases 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000036651 mood Effects 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 210000003024 peritoneal macrophage Anatomy 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 210000001525 retina Anatomy 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000002936 tranquilizing effect Effects 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 235000019166 vitamin D Nutrition 0.000 description 3
- 239000011710 vitamin D Substances 0.000 description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 description 3
- 229940045997 vitamin a Drugs 0.000 description 3
- 229940046008 vitamin d Drugs 0.000 description 3
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 235000008440 Crataegus cuneata Nutrition 0.000 description 2
- 244000160089 Crataegus cuneata Species 0.000 description 2
- 235000014283 Crataegus pinnatifida var major Nutrition 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 102000008857 Ferritin Human genes 0.000 description 2
- 108050000784 Ferritin Proteins 0.000 description 2
- 238000008416 Ferritin Methods 0.000 description 2
- 206010053759 Growth retardation Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 241000607764 Shigella dysenteriae Species 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 108010046075 Thymosin Proteins 0.000 description 2
- 102000007501 Thymosin Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 241001247821 Ziziphus Species 0.000 description 2
- 244000126002 Ziziphus vulgaris Species 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 230000002790 anti-mutagenic effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000003464 asthenopia Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000000496 cardiotonic agent Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000002279 cholagogic effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- MDZKJHQSJHYOHJ-UHFFFAOYSA-N crataegolic acid Natural products C1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MDZKJHQSJHYOHJ-UHFFFAOYSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 208000002925 dental caries Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 231100000001 growth retardation Toxicity 0.000 description 2
- 235000020717 hawthorn extract Nutrition 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 230000000971 hippocampal effect Effects 0.000 description 2
- 239000000413 hydrolysate Substances 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 230000004130 lipolysis Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- MDZKJHQSJHYOHJ-LLICELPBSA-N maslinic acid Chemical compound C1[C@@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MDZKJHQSJHYOHJ-LLICELPBSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 206010027175 memory impairment Diseases 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 229940117954 naringenin Drugs 0.000 description 2
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 2
- 235000007625 naringenin Nutrition 0.000 description 2
- 210000004493 neutrocyte Anatomy 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 210000001328 optic nerve Anatomy 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 229940007046 shigella dysenteriae Drugs 0.000 description 2
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- QWWVBNODQCWBAZ-WHFBIAKZSA-N (2r)-2-amino-3-[(2r)-2-carboxy-2-(methylamino)ethyl]sulfanylpropanoic acid Chemical compound CN[C@H](C(O)=O)CSC[C@H](N)C(O)=O QWWVBNODQCWBAZ-WHFBIAKZSA-N 0.000 description 1
- DGIMBMZJSZEZJD-ZLELNMGESA-N (2s)-2-amino-5-(ethylamino)-5-oxopentanoic acid Chemical compound CCNC(=O)CC[C@H](N)C(O)=O.CCNC(=O)CC[C@H](N)C(O)=O DGIMBMZJSZEZJD-ZLELNMGESA-N 0.000 description 1
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- BMUDPLZKKRQECS-UHFFFAOYSA-K 3-[18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoic acid iron(3+) hydroxide Chemical compound [OH-].[Fe+3].[N-]1C2=C(C)C(CCC(O)=O)=C1C=C([N-]1)C(CCC(O)=O)=C(C)C1=CC(C(C)=C1C=C)=NC1=CC(C(C)=C1C=C)=NC1=C2 BMUDPLZKKRQECS-UHFFFAOYSA-K 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 240000000073 Achillea millefolium Species 0.000 description 1
- 235000007754 Achillea millefolium Nutrition 0.000 description 1
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 1
- 208000001395 Acute radiation syndrome Diseases 0.000 description 1
- 206010054196 Affect lability Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 102400000059 Arg-vasopressin Human genes 0.000 description 1
- 101800001144 Arg-vasopressin Proteins 0.000 description 1
- 102400000748 Beta-endorphin Human genes 0.000 description 1
- 101800005049 Beta-endorphin Proteins 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 108091060290 Chromatid Proteins 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 241000005787 Cistanche Species 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010057315 Daydreaming Diseases 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 101710169609 Hemoglobin-3 Proteins 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 206010061998 Hepatic lesion Diseases 0.000 description 1
- 235000003935 Hippophae Nutrition 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 239000004158 L-cystine Substances 0.000 description 1
- 235000019393 L-cystine Nutrition 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 208000000501 Lipidoses Diseases 0.000 description 1
- 206010024585 Lipidosis Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- VZUNGTLZRAYYDE-UHFFFAOYSA-N N-methyl-N'-nitro-N-nitrosoguanidine Chemical compound O=NN(C)C(=N)N[N+]([O-])=O VZUNGTLZRAYYDE-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108700022034 Opsonin Proteins Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 1
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241001417949 Psychrolutidae Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000019155 Radiation injury Diseases 0.000 description 1
- 206010068142 Radiation sickness syndrome Diseases 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000219100 Rhamnaceae Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 1
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010039984 Senile osteoporosis Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 241000726445 Viroids Species 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 206010048259 Zinc deficiency Diseases 0.000 description 1
- LEBBDRXHHNYZIA-LDUWYPJVSA-N [(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] n-[(z)-1,3-dihydroxyoctadec-4-en-2-yl]carbamate Chemical compound CCCCCCCCCCCCC\C=C/C(O)C(CO)NC(=O)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O LEBBDRXHHNYZIA-LDUWYPJVSA-N 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940039750 aconitine Drugs 0.000 description 1
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000003035 anti-peroxidant effect Effects 0.000 description 1
- 230000003005 anti-senility effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WOPZMFQRCBYPJU-NTXHZHDSSA-N beta-endorphin Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CC=CC=C1 WOPZMFQRCBYPJU-NTXHZHDSSA-N 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 230000037180 bone health Effects 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 235000012721 chromium Nutrition 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- OORMXZNMRWBSTK-LGFJJATJSA-N dammarane Chemical compound C1CCC(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@H](C)CCCC(C)C)[C@H]4CC[C@@H]3[C@]21C OORMXZNMRWBSTK-LGFJJATJSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000009189 diving Effects 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- ZOOODBUHSVUZEM-UHFFFAOYSA-N ethoxymethanedithioic acid Chemical compound CCOC(S)=S ZOOODBUHSVUZEM-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 229940109738 hematin Drugs 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940095990 inderal Drugs 0.000 description 1
- 230000000053 inderal effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000003446 memory effect Effects 0.000 description 1
- 230000005055 memory storage Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 239000004223 monosodium glutamate Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000005195 poor health Effects 0.000 description 1
- 230000004793 poor memory Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229960003581 pyridoxal Drugs 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004243 retinal function Effects 0.000 description 1
- 239000000790 retinal pigment Substances 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 231100000188 sister chromatid exchange Toxicity 0.000 description 1
- 230000009645 skeletal growth Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 230000002557 soporific effect Effects 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000000515 tooth Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明属于儿童营养饮料技术领域,尤其以枸杞子、大枣、龙眼肉、山楂、沙棘、菊粉、牛黄酸、L-茶氨酸、乳酸钙、乳酸亚铁、葡萄糖酸锌、辅料制作的儿童营养饮料。该产品制作工艺为:原料混合粉碎、二次沸水浸提、两次滤液混合加入强化原料溶化、搅拌均匀、过滤、灌装封盖、杀菌、检验合格包装成为正式产品。该产品含有枸杞子、大枣、龙眼肉、山楂、沙棘、菊粉、牛黄酸、L-茶氨酸、钙、铁、锌等原料,健脾胃、促消化、补气养血,具有提高儿童免疫力、促进儿童生长和大脑发育、提高记忆力、改善睡眠、调节肠道功能、预防龋齿等功能。
Description
一、技术领域:本发明属于营养饮料,尤以枸杞子、大枣、龙眼肉、山楂、沙棘、菊粉、牛黄酸、L-茶氨酸、钙、铁、锌等原料,采取先进工艺加工而成的儿童营养饮料。
二、背景技术:该发明以枸杞子、大枣、龙眼肉、山楂、沙棘、菊粉、牛黄酸、L-茶氨酸、钙、铁、锌等原料制成的儿童营养饮料,该产品营养高、味好、健脾胃、促消化、补气养血,而且具有提高免疫力,促进儿童生长大脑发育、增强记忆力、改善睡眠、调节肠道微生态、预防龋齿等功能。目前市场上还没有儿童营养饮料产品,研制该产品可以给饮料行业提供一种新型的饮料品种,该饮料口感柔合、味道纯正,而且还具有营养功能,特别介适合儿童青少年。
三、发明内容:随着我国经济的飞速发展,人们的生活、工作、学习节奏加快,给在处于生长发育期的少年儿童生活和学习带来很大的压力,饮食不规律、不均衡和缺乏营养,加上一些不良的生活的习惯,严重影响他们的生长发育。为了提高我国的人口素质和保证少年儿童的正常生长发育,在日常生活中增加必需的营养与摄入量,对促进少年儿童的生长发育具有重要意义。
四、原料配方:枸杞子5千克、大枣6千克、龙眼肉3千克、山楂5千克、沙棘6千克、菊粉2千克、牛黄酸0.3千克、L-茶氨酸0.2千克、乳酸钙4千克、乳酸亚铁0.18千克、葡萄糖酸锌0.2千克、辅料。
五、技术方案
(一)枸杞子(Lyciam barbarnm extraat),枸杞子为茄科植物枸杞成熟果实。性平,味甘。归肝、肾经。具有滋补肝肾、益精明目、润肺的功效。用于虚劳精亏、腰膝酸痛、眩晕耳鸣、内热消渴、血虚萎黄、目昏不明等。现代医学研究认为,枸杞子具有增强免疫力、抗疲劳、降血压、降血脂、降血糖、保护肝脏、减肥、抗衰老、抗癌等功能。
化学成分:枸杞子含多糖、氨基酸、甜菜碱、胡萝卜素、维生素B、维生素C、烟酸等多种维生素以及锰、铬、锌、铜、镁、钙、锗、钴等微量元素。
药理作用:1、增强免疫力:小鼠灌服水提取物或肌注醇提取物均能显著增强其网状内皮系统对印度墨汁的吞噬能力。水提取物或枸杞多糖均能促进小鼠腹腔巨噬细胞吞噬功能和血清中溶菌酶活性。给正常或老年小鼠灌服或腹枸杞多糖,能显著增强腹腔巨噬细胞c3b和Fc的受体数和活力,可使老年小鼠抑制性T细胞调节抗体功能恢复到成年小鼠的水平。枸杞多糖纯品比粗品具有更显著的免疫应答效应,各项免疫指标(包括非特异性免疫的免疫器官质量、巨噬细胞吞噬作用、特异性体液免疫的血清溶血素,特异性细胞免疫中的退发型变态反应、淋巴细胞转化率、E玫瑰花结形成等)均有显著的差异。
2、保护肝脏、抗脂肪肝:枸杞子提取物对保护肝脏和抗脂肪肝具有一定的作用。现代医学研究发现,枸杞中含有一种有效成分—甜菜碱,它对治疗肝脏疾病很有效。实验表明,甜菜碱有抑制脂肪在肝细胞内沉积,促进肝细胞再生的作用。另外,枸杞的中甜菜碱能防止肝脏内过多的脂肪贮存,有防脂肪肝的作用,据报道,长期经大鼠饲喂水提取物或甜菜碱饲料对ccl4引起的肝损害有保护作用,能明显降低转氨酶及肝中脂质的变化,可抑制肝中脂质沉积及促进肝细胞新生,对肝脏脂质过氧化损伤有明显的保护作用。
3、抗辐射:枸杞多糖2(LBP2)能明显促进辐射损伤小鼠免疫功能的恢复,可使受照射的小鼠胸腺指数脾细胞对ConA,LPS的增殖反应等均明显增强。表明其对放射病的治疗有重要意义。
4、抗应激:电击加低剂量Y射线照射后,大鼠的脾重指数明显降低,大脑皮层指数明显升高,脾和大脑皮层总脂含量明显降低脂质过氧化产物丙二醛明显增加。腹部注射枸杞多糖可见给药组脾和脑匀浆总脂水平接近对照组,脾匀浆MDA含量显著降低。表明枸杞多糖具有抗应激作用。
5、耐缺氧:枸杞子煎剂给小鼠腹腔注射,其耐缺氧能力与对照组生存时间27.9±1.3min相比较,枸杞子为37.5±2.5min。表明枸杞子具有耐缺氧作用。
6、抗疲劳:枸杞子可提高羟脯氨酸浓度,从而提高肌力使抗疲劳能力增强。枸杞子还可明显延长小鼠的负重游泳时间,具有抗疲劳作用,也有强壮作用。
(二)大枣(Jujub fruit),又名红枣。为鼠李科植物枣的干燥果熟。性温,味甘。归脾、胃经。具有补脾益气,养血安神、生津液、解药毒、缓和药性的功效。现代医学研究认为,大枣增强免疫力,保护肝脏、抗疲劳、降低胆固醇、抗氧化、抗肿瘤、抗衰老等功能。
化学成分:大枣含蛋白质、多种氨基酸、皂甙、黄酮、生物碱、有机酸、甾醇、多糖、维生素A、维生素B2、维生素C、烟酸、维生素E和胡萝卜素、钙、磷、铁、镁等。
药理作用:1、增强免疫力:研究表明,用大枣煎剂8.25g/kg给小鼠灌胃7天能明显提高其腹腔巨噬细胞吞噬鸡红细胞的百分数和吞噬指数;15天时对环磷酸酰胺所致小鼠的细胞,血小板和血红蛋白减少均有增加和恢复作用,对骨髓造血功能也有保护作用。另据报道,大枣中性多糖(TDP-N)能引起小鼠腹腔细胞内Ca2+浓度明显升高。大枣多糖给D-半乳糖衰老模型小鼠灌服,可明显抗胸腺、脾脏萎缩。
2、保护肝脏:研究证实,对四氯化碳肝损伤的家兔,连续服用大枣煎剂7天,血清兔蛋白和白蛋白明显提高,证明大枣有保肝作用。研究还证明,大枣煎剂还能明显增加正常小鼠肝脏血流量,而且能防止四氯化碳所致的肝脏血流量下降,同时也能减轻小鼠肝细胞肿胀、坏死及脂变程度。另外大枣含有三萜类化合物成分,可抑制肝类病毒的活性。红枣还能提高体内单核吞噬细胞系统的吞噬功能,有保护肝脏的作用。
3、增加肌肉力量、抗疲劳:据报道,用30%大枣煎剂体重0.3ml/kg给雄性小鼠腹腔注射,饲养3周,结果大枣组小鼠平均体重增加3.0g,对照组则平均增加1.6g,两组为2min30S,因此表明大枣具有增加肌力和抗疲劳作用。另据报道,给小鼠服用大枣煎剂1.25-8.25g/kg,7天后明显延长小鼠的游泳时间,3周后体重明显增加表明具有强壮作用。
4、镇静安神:大枣中所含的柚配质C糖甙(糖苷类)能降低动物的自发运动、刺激反射作用,强直性木僵作用,对中枢神经系统有抑制作用。另据日本报道,大枣乙醇提取物中分离出的黄酮-双-葡萄糖苷A经药理实验证明有中枢神经抑制作用,且有镇静,催眠作用。
5、抗惊厥:研究表明,大枣具有明显的抗惊厥作用,用甘麦大枣汤治疗情绪8倒(0-5岁),结果表明,在3-4周内均发现有抑制效果,研究表明,甘麦大枣汤镇静作用相配合可发挥更强的药效,由于该方剂的安静作用及兴奋作用是在既不引起患儿的睡意,又不降低其活性的情况下发挥的,故对婴儿是安全有效的。
6、降血压:大枣中所含苯甲醇糖苷、柚配质(糖苷等多种化合物)具有显蓍的降血压的作用。
7、抗肿瘤:大枣具有抑制癌细胞增殖作用。其中的桦木酸和山楂酸对S180有抑制作用。大枣对N-甲基-硝基-N-亚硝基胍(MNNe)诱发的大鼠胃腺癌有一定抑制作用。用100цg/ml、MNNe处理的大鼠7个月后,连续8个月喂服枣干果(1g/d)其大鼠胃腺发生率与对照组MNNe连续喂10个月)相比有显着差异。应用姐妹染色体互换技术,给小鼠灌服0.58/ml 大枣水提取液,能明显降低环磷酸酰胺所致姐妹染色体单体互换率的升高现象,表明大枣有抗突变作用。大枣的有效成分达玛烷型皂苷与人参皂苷是同系物具有抗突变活性。
8、抗氧化:大枣提取物对小鼠红细胞、血浆、肝组织中SOD及MDA含量进行的影响实验结果表明,小鼠饮用不同浓度的大枣提取物具有清除自由基和增强机体抗脂质过氧化的作用。
9、强健体质、延衰:在我国民间流传“一日吃三枣,终身不显老”的养生谚语。大枣是一种性味甘平的补气养血佳品。数千年来,红枣备受人们的珍爱,也被视为滋养血脉、强健脾胃的保健食品。正如《本草纲目》所说,大枣安中养脾气、平胃气、通九窍、助十二经、补少气、少津液、身中不足、大惊四肢重、和百药、久服轻身延年。据报道,英国医学研究发现,大枣对身体虚弱者的实验表明,凡是连续吃大枣的健康恢复的速度比单纯吃维生素类药物者快3倍以上。
(三)龙眼肉(Long an),又名桂圆。为无患子科植物龙眼树的成熟果肉。性温、味甘,归心、脾经。具有补益心脾、益气血、安神等功效。用于气血不足、心悸怔忡,健忘失眠、贫血萎黄。现代医学研究认为,龙眼肉具有促进生长发育、增强免疫力、抗疲劳、抗应激、抗癌、延缓衰老等功能。
化学成分:龙眼肉含蛋白质、氨基酸、葡萄糖、酒石酸、胆碱、维生素A、维生素B1、维生素B2、维生素D、维生素C等成分。
药理作用:1、提高免疫力:龙眼肉提取液给小鼠灌服20ml/kg,7月能明显增加脾脏重量。15ml/kg 10日可提高小鼠炭粒廓清指数,具有提高免疫力作用。
2、促进生长发育:龙眼肉水提液1g/ml给小鼠灌服,可使由利血平所致小鼠体重下降,活动减少,等虚弱症状有明显好转,对正常小鼠灌服20ml/kg 6日可增加体重,能促进生长发育。
3、抗应激:动物实验表明,龙眼肉提取液能显著延长常压下小鼠耐缺氧时间,在-18-20℃环境中,小鼠耐低温数明显增多;在48±1℃温箱中,小鼠耐高温时间比对照组显著延长。
4、抗疲劳:龙眼肉提取液能延长小鼠负重游泳时间。
5、增强记忆力:龙眼肉具有补心养脾、益血安神的功效,凡因心脾两虚所致的健忘、失眠、心悸、智力减退都有一定的作用。用龙眼肉5枚、大枣5枚泡水喝早晚各一次,具有补脾生血、益脑增智的功效。尤其适应于气血不足所致的脑髓血虚、记忆减退者。
6、防治失眠多梦:祖国医学认为,龙眼肉性温、味甘,具有开胃益脾、养血安神、壮阳益气、补虚益智的功效。临床用于治疗心脾两虚、血气不足所致的心悸。每晚睡前食用5枚龙眼肉,具有养血安神的功效。非常适宜心脾两虚所致的失眠多梦者。
7、抗菌:龙眼肉水浸剂1∶2在试管内对奥杜盎氏小芽孢癣菌有抑制作用;煎剂对痢疾杆菌有抑制作用。
8、抗衰老:龙眼肉能选择性的能抑制使人衰老的黄素蛋白酶-脑B型单胺氧化酶(MAO-B)的活性。所以龙眼肉能成为潜在的具有MAO-B抑制活性的抗衰老食品。
(四)山楂(Hawthorn),又名山里红果。为蔷薇科植物的山楂的果实。性微温、味酸、甘。归脾、胃、肝脏经。具有消食化积、健胃、活血散瘀等功效。用于肉食积滞、小儿乳积、脘腹胀痛、痢疾、泄泻等。现代研究认为山楂有增强免疫力、抗菌、强心、耐缺氧、保肝、降血脂、抗肿瘤等功能。
化学成分:山楂含有机酸、黄酮、维生素C、胡萝卜素等成分。
药理作用:1、增强免疫力:山楂对兔血清溶菌酶的含量、血清血凝抗体滴度、心血T淋巴细胞E玫瑰花环形成率及T淋巴细胞转化率均有显著的增高作用,说明山楂对体液免疫和细胞免疫均有促进作用。
2、助消化:山楂能增加胃中消化酶的分泌、促进消化。所含的脂肪酶可促进脂肪分解;所含的山楂酸等有机酸可提高蛋白酶的活性,使肉食易被消化。动物实验表明,山楂水煎剂对大鼠胃液分泌有明显的促进作用。较大鼠基础胃液分泌量增加2.19倍。
3、抗菌:山楂水煎剂对金黄色葡萄球菌、炭疽菌均有较强的抑制作用。山楂核溜油对痢疾杆菌、大肠杆菌也有明显的抑制作用。
4、强心:山楂提取物对蟾蜍在体及离体正常及疲劳心脏均有一定的强心作用。对心脏收缩增强率在20%-30%之间,且持续时间较长。另据报道,山楂能增加心肌收缩力和心排出量,山楂三萜酸对自然疲劳或10%水合氯醛所致的衰弱心脏有恢复搏动的作用。
5、抗心律失常:山楂浸膏对家兔因脑垂体后叶素引起的心律不齐有抑制作用;山楂黄酮及皂甙可使家兔因乌头碱引起的心律失常也有促进正常的作用。
6、增加冠脉血流量:山楂颗粒对兔、犬都有扩张冠脉血管、增加冠脉血流量的作用。用放射性86铷测量证明,山楂黄酮、水解产物均能增加小鼠心肌营养性血流量,其中以山楂水解产物作用较强。在增加冠脉血流量的同时,还能降低心脏耗氧量和氧利用率。此外,山楂对家兔实验性急性心肌缺血有保护作用。
7、耐缺氧:山楂与心得安一样有非常显著的耐缺氧作用,能延长小鼠的存活时间。
8、抗疲劳:山楂多糖具有抗疲劳的作用。这种多糖能降低体内乳酸,并可显著延长机体耐缺氧时间,提高缺氧能力,降低血清尿素氮,促进糖原储备提高肝糖原含量,因而具有抗疲劳作用。
9、镇静催眠:动物实验表明,山楂能显著延长小白鼠戊巴比妥钠睡眠持续时间。
(五)沙棘(Seahuckehorn),沙棘为胡颓子科植物沙棘的果实。性温、味酸涩。具有祛痰止咳、消食化滞、活血散瘀的功效。用于消化不良、咳嗽多痰、瘀血闭经等。
现代医学研究认为,沙棘具有增强免疫力、恢复体力、消除疲劳、强精神、耐心肌缺血缺氧、降血压、降血脂、防治动脉硬化、脑血栓、抗氧化、抗衰老、抗癌有较好的预防和药理作用。
化学成分:沙棘含20多种氨基酸,不饱和脂肪酸、生物碱、黄酮、单糖类、12种有机酸、维生素C、E、A、B1、B2、叶酸、胡萝卜素、钙、32种微量元素等200多种对人体有益的生物活性物质。被中外专家誉为“维生素的宝库”。
药理作用:1、提高免疫力:沙棘汁和沙棘油可增加免疫器官的重量,提高血清半数容血值抗体效价和再次抗原刺激抗体效价。促进巨噬细胞吞噬功能。沙棘黄酮的作用类似沙棘汁和沙棘油,并可使免疫功能低下的小鼠血抗体水平升高。
2、促进生长发育:沙棘浓缩汁中的维生素C可促进幼儿动物(豚鼠)的生长发育,对维生素C缺乏有治疗作用。
3、保护肝脏:沙棘籽油能减轻四氯化碳引起的小鼠肝损伤,对四氯化碳所致肝损伤小鼠丙二醛(MAD)和血清谷丙转氨酶(SGPT)的升高有明显的抑制作用,并能抑制扑热息痛所致肝脏的MDA增高,对抗受损肝脏谷胱甘肽(GSH)。另外,沙棘果汁可保护ccl4对乙酰氨基酚所致的肝损伤。
4、抗过敏:沙棘总黄酮腹腔注射能抑制小鼠的被动皮肤过敏反应,其抗过敏作用环节可能不在改善靶器官和细胞的反应,也不像扑尔敏药物等竞争靶细胞受体而发挥作用。可能与抑制抗原的结合或介质释放等因素有关。
5、促进造血功能:沙棘原汁对造血细胞有促进及生长作用,此作用可能与沙棘富含的维生素E、A、C以及各种氨基酸有关。
6、抗心肌缺血和心律失常:沙棘全成分腹注或静注,对小鼠和大鼠急性心肌缺氧、缺血有保护作用,使心律失常从100降为0,沙棘总黄酮对小鼠、大鼠、豚鼠能增加心肌营养流量,对抗缺血性心律失常,改善心肌缺血,增进心脏功能。
8、美容养颜:研究表明,沙棘含有维生素C、E、A等营养物质,可营养滋润皮肤,促进细胞代谢和上皮组织再生,具有抗氧化、抗过敏、祛除黄褐斑、抑菌、延缓皮肤衰老等,保护皮肤自然色泽的作用。
9、抗辐射:用7.5Gy60co射线照射小鼠、与照射前1小时和照射后15分钟经口服沙棘油4.75g/kg,小鼠30天存活率显著提高。经口服11.9g/kg,5.95g/kg和2.98g/kg时均能提高脾造血灶数,5.95g/kg能使骨髓有核细胞数显著增高,能显著降低骨髓象染红细胞微核率,对小鼠急性放射病有防护作用。此外,沙棘还有降血脂、抗血栓、抗氧化、抗肿瘤、延缓衰老等作用。
(七)牛黄酸(Taurien),又名牛胆酸,存在于牛的胆汁,是一种含硫氨基酸,但不参与蛋白质的合成,在体内由蛋氨酸、半胱氨酸通过脱羧氧化合成。牛黄酸以游离氨基酸的形式广泛分布于体内各组织器官,如中枢神经系统、视网膜、肝脏、骨骼肌、血细胞、胸腺及肾上腺等,尤其脑组织含量最高。
牛黄酸的化学名称,为α-氨基乙黄酸,分子量为125.4;为白色针状结晶或结晶粉末,无臭、味微酸,熔点为300℃,易溶于水和乙酸;不溶无水乙醇、乙醚、丙酮之类。
生理功能:1、增强免疫力功能:牛黄酸对免疫功能调节起着重要的作用。白细胞通过产生次氯酸来杀死细菌,但若次氯酸过多时反应破坏白细胞自身,牛黄酸则可与次氯酸结合,生成无毒物质,自然就会保护白细胞。近年来又有研究发现,牛黄酸可以提高机体内特异性和非特异性免疫功能,促进淋巴细胞产生的白细胞素-1,增强中性粒细胞吞噬杀菌的活性,对婴幼儿机体免疫细胞功能起着重要的作用,提高抗病能力。
2、清热退烧:当儿童受到风寒感冒侵害时,牛黄酸可发挥清热退烧的作用,进而增强人体抵抗力。牛黄酸还是含硫氨酸;能促使淋巴细胞的生长和繁殖。它还能清热镇痛,缓解人体自己因抵御病毒而起动自身调节,防御系统产生的症状—发烧。
3、利胆护肝:牛黄酸能促胆汁的合成与分泌,对受损的肝细胞有促进恢复作用。并可改善肝功能。牛黄酸还能预防脂肪肝及肝内胆汁郁滞,中和细胞毒素,降低次级酸的毒素,保护肝细胞膜。因此其具有良好的利胆,保肝和解毒作用。
4、促进大脑发育:牛黄酸是中枢神经含量最多的游离氨基酸之一,在脑发育中扮演着重要的角色。儿童在发育的脑组织的含量又明显,高于成年后。科学研究发现,牛黄酸可促进大脑细胞尤其是海马细胞结构和功能的发育。牛黄酸还能促进大脑海马细胞生长发育,延长细胞的存活时间,缺乏牛黄酸会影响大脑的生长发育、智力发育迟缓。另报道,牛黄酸具有维持人体大脑正常的生理功能,促进婴幼儿大脑发育。由于婴儿体内牛黄酸生物合成速度级低,必须从外界补充,如果摄入不足,则会影响脑及脑神经的正常发育,进而影响婴幼儿智力发育。
5、提高学习记忆力:科学研究牛黄酸可促进大白鼠的学习记忆能力。补充适量的牛黄酸,不仅能提高大鼠的学习记忆速度,而且还可以提高学习记忆正确性。这是因为牛黄酸可通过提高蛋白质的利用率来促进生长智力发育。另有报道,中枢神经系统的一些肽类物质参与信息在脑内的加工过程,它们可以调节记忆储存和提取过程,牛黄酸可通过海马多皮层内β-内啡肽及精氨酸加压素含量的增加而参与学习记忆过程中起重要作用。
6、保护视网膜、抗视疲劳:视网膜色素细胞中含有较多浓度的牛黄酸,但细胞本身不能合成牛黄酸。因此,为维持正常的视觉功能,保护视力,需补充充足的牛黄酸。婴幼儿如果缺乏牛黄酸,会发生视网膜功能紊乱与生长发育迟缓。另外牛黄酸还具有改善视力和缓解视疲劳。
7、抗疲劳:牛黄酸对用脑过度、工作及运动和疲劳具有消除作用。研究表明,过多的自由基会导致核酸主链和蛋白质交联或多肽链断裂,生物膜通透性增加,细胞内物流逸出、细胞功能紊乱,ATP生成下降,能量供应不足及组织严重损伤等,导致人体工作能力下降并产生疲劳。牛黄酸具有提高机体抗氧化防御功能,对延缓疲劳产生,提高运动能力有重要意义。运动员在补充牛黄酸后,多项功能指标均显著增加,试验证实,牛黄酸能提高机体LDH活力及肌糖原和肝糖原的含量,降低血乳酸含量,因而对机体具有抗疲劳作用。
此外,牛黄酸还具有降血压、抗氧化、抗肿瘤、延缓衰老作用。
(八)L-茶氨酸(L-Theanine),茶氨酸是存在于茶叶中的一种特殊的氨基酸。茶氨酸是谷氨酸的乙胺诱导体,它在茶树根中由谷氨酸和乙胺合成,通过树杆运送叶中贮藏,在阳光照射下转化为儿茶素。自然界存在的茶氨酸均为L型,纯品为白色针状结晶,熔点217-218℃(分解),极易溶于水,不溶于乙醇、乙醚,水溶液呈微酸性,有焦糖及类似味精的鲜爽味。
生理功能:1、提高免疫力:据有关报道,国外研究发现,当接触到大量的乙胺时,人体血液免疫细胞“Y·S·T细胞”可以产生抗感染的化学物质,该细胞是抵御许多病菌、病毒、真菌和寄生虫感染的第一道防线。而茶氨酸在人体肝脏内会分解为乙胺,这样会使外用血液Y·S·T细胞接触到乙胺,以促进干扰素的分泌。从而提高人体免疫力。另一方面,茶氨酸可以作为谷氨酸的共体,通过促进谷胱甘肽的形成来提高免疫力。另有报道,L-胱氨酸和L-茶氨酸合用能显著提高肝脏中谷胱苷肽水平,以增强免疫特异性1g G抗体的产生。
2、保护脑神经细胞:茶氨酸对脑组织有保护作用,可避免由脑缺血所致脑神经细胞死亡。谷氨酸是兴奋性神经传递物质,在神经细胞内含量为1-10mm01/L,当脑缺血时,细胞内因O2供应中断,使细胞内的能源物质三磷酸腺苷(ATP)生成量减少,而逐渐枯竭,神经细胞膜分离谷氨酸过多向细胞释放,并作用受体,使细胞内钙离子浓度持续增高,激发各种分解酶活性,并最后作用于细胞而使之破坏、死亡。而茶氨酸对谷氨酸受体有竞争保护作用,因此茶氨酸对脑组织有保护作用,可避免由脑缺血所致脑神经细胞死亡。
3、放松精神压力:当一个人因学习、工作等原因引起精神紧张和压力,茶氨酸对舒缓放松精神压力有特效。研究表明,动物和人类总是在大脑表面上产生非常弱的脉冲即脑波。脑波与人的精神状态有关。根据频率的脑波可分为α·B.S及θ波,其中α波是人在安静时(松弛状态出现的;θ波是在人打盹时出现的),研究发现,茶氨酸可以促进α波的产生,使人产生舒畅、愉快的感觉,并且茶氨酸不会引起θ波数量增加,由此茶氨酸在使人的情绪放松的同时还有助于注意力集中。据日本研究发现,人体摄取茶氨酸以后,测定大脑波的结果是α波明显增大,而且心情、心境感到轻松愉快、头脑清醒、清晰状态。研究还发现,茶氨酸还具有提高视觉作用和听觉作用注意力效果。
4、镇静:茶氨酸具有镇静的作用。它可以通过抑制大脑皮层兴奋达到抗应激效应,并且茶氨酸可以抵抗咖啡碱产生的兴奋作用。据日本研究报道,茶氨酸其镇静效果通过脑α波的已测定确认结果显示,饮茶氨酸水溶液的试验比饮水的对照组脑α波(表示安静时的脑波)显著增加。茶氨酸还能明显提高不安程度精神状态者的α-脑波,比对照组只饮水人的精神不安者,α脑波会增加1-2倍,使不安者安静。
5、提高学习记忆力:研究通过操作行为、回避、跳台及复杂的迷宫试验,考察茶氨酸对小鼠学习记忆能力的影响。研究发现,服用茶氨酸小鼠的多巴胺浓度高,并且学习能力和记忆能力也都有一定的提高,而且茶氨酸对学习记忆力的增强作用随剂量的增加而增大。目前研究证明,茶氨酸能提高学习和记忆作用与活化脑内中枢神经递质5-羟色胺有关。另据日本研究,用茶氨酸喂大白鼠使其肠道吸收后,由血液输送进入肝脏和脑部。通过对脑线条件的影响能显著增加脑内神经递质多巴胺。多巴胺是去甲肾上腺素的前驱体,对神经细胞兴奋的传达具有重要作用。即茶氨酸对多巴胺性能传递具有重要的功能。
6、抗疲劳:茶氨酸具有抗疲劳作用。有人研究发现,经口服给小鼠不同剂量的茶氨酸30天,能显著延长小鼠负重游泳时间,减少糖肝原的消耗量,降低运动时血清尿素氮水平;对小鼠运动后血乳酸升高有明显的抑制作用,能促进运动后血乳清的消除。因此茶氨酸具有抗疲劳作用。其机理可能使与茶氨酸可抑制5-羟色胺分泌,促进儿茶酚胺分泌,增强脑组织的多巴胺(DA)含量有关。
此外,茶氨酸还具有缓解妇女经前综合症、降血压、抗肿瘤等功效。
(九)钙(Ca),钙是构成人体必需的营养素,也是人体含量最多的矿物质。在人体内的总量大约为1200克,其中99%存在骨骼和牙齿中,其余钙存在于神经细胞、机体组织、血液和其他体液中。钙不仅是构成机体完整不可缺少的组成部分,而且在机体的生长发育和生理生化过程中对维持生命起着重要的作用。
钙为多功能营养素,除了构成骨骼和牙齿外,许多生理功能也需要钙的参与,如血液凝固,神经传导、肌肉活动、维持正常的心跳、刺激激素分泌、激活酶反应和调节体液渗透压等重要作用。同样钙对骨骼生长发育也有在重要的作用,钙可使青少年骨骼生长发育加速,提高骨骼中骨矿物含量,以达到最佳骨峰值,老年人,绝经妇女补钙是防治骨质疏松的重要手段。
生理功能:1、促进骨骼生长:钙是人体内含量最多的营养素,是构建和保持骨骼健康所必需的。研究证明,在儿童青少年时期摄入充足的钙,可以促进骨骼生长发育,45%的骨生长在青少年时期,因此儿童在骨形成时需要吸收充足的钙到骨的结构中,骨组织才能不断的吸收重建,所以维持这个循环需要不断的补充钙,以促进骨骼的生长发育。最关键的是在儿童青少年时期,此时,骨骼和牙齿生长速度很快,身体迅速长高需要大量的钙以促进骨骼再生长。
2、调节大脑功能:钙在大脑和机体生长发育及新陈代谢过程中有着重要的调节作用。钙是脑神经代谢的激活剂,大脑皮层由各种神经元、神经胶质、神经纤维组成。在钙离子的激活下,机体内的各种酶才能有活性,神经肌肉兴奋和抑制活动以及所有组织器官的功能均与钙离子有直接关系。因此钙离子对大脑和整个机体代谢有着重要的调节作用。充足的钙具有正确传达神经细胞输出信息功能,保证大脑持续工作,抑制脑神经异常兴奋的重要物质。钙不足时脑神经异常兴奋、情绪不稳定、抗病能力下降、智力发育迟缓、脑反应能力差。
3、防治近视:据有关研究认为,儿童青少年正处于发育高峰期,如钙摄入不足,可以使正常发育的眼球壁-巩膜的弹性降压,由眼球内的液体压力相对升高,致使眼球的前后径拉长而导致近视。
4、驱铅:据医学研究证明,补充钙剂可治疗儿童铅中毒。研究者对746名3-6岁儿童分为2组,一组每日分3次口服钙,另一组暂不给予服用钙剂,两组观察时为3个月,结果3个月后,口服钙剂的儿童铅水平明显下降,另一组儿童铅水平有缓慢上升的趋势。由此表明,钙可以防止铅的吸收和驱铅的作用,对防止儿童铅中毒有一定的意义。
5、减肥:研究证明,钙与脂肪代谢有密切关系,具有抑制储存脂肪激素的作用。研究发现,低钙饮食中者肥胖患者居多。其血浆维生素B3也显著增高,引起细胞内钙离子浓度升高,是脂肪合成,抑制脂肪分解,导致体重增加和肥胖。而高钙则显著降低血浆维生素D3的含量,减少脂肪细胞内脂质合成,有一种转基因肥胖小鼠用高钙饲养后脂肪合成降低、分解增强、体重下降、补钙可促进脂肪燃烧。因此补钙具有减肥作用。
此外,钙还有防治老年骨质疏松、降血压、降血脂、防治心血管疾病、防治肾结石、抗癌等功能。
(十)铁(Fe)铁是人体含量最多的一种必需微量元素,在人体内总量约为4-5克,其中60-70%以血红蛋白3%以肌红蛋白、1%以含铁酶的形式存在,其余30%则以贮备铁的形式存在,贮备铁主要以铁蛋白的形式存在于肝脏、脾脏和骨髓中。铁在人体中有多种重要的生理功能,其中最主要的是作为血红蛋白和肌红蛋白及一些呼吸酶的成分,参与体内氧与二氧化碳的转运,携带氧到组织细胞,并将二氧化碳带出。其机理是铁在骨髓组织中与原卜啉结合形成正铁血红素,参与血红蛋白的合成。
生理功能:1、增强免疫功能:科学研究发现,缺铁的儿童、老人的免疫力功能比正常儿童、老人要低,这是因为人体内的铁元素含量不足,免疫系统中起控制调节作用的T细胞含量就会下降,从而造成免疫系统无法有效运作。
另据报道,铁可以激活多种酶。当铁缺乏时,核糖核酸活性降低,肝、脾和胸腺蛋白质合成减少,使免疫功能出出各种异常,如淋巴样组织萎缩,胸淋巴细胞及外周血T细胞减少,淋巴细胞增殖能力、空斑形成细胞(PFC)产生巨噬细胞和自然杀伤细胞(NK)功能受抑制。铁缺乏还可以干扰细胞内含铁金属酶的作用。含铁核糖核苷酸还原酶的活性降低,可以使吞噬细胞合成过氧化物减少;以致影响这些细胞的杀菌力。
2、抗感冒:科学研究发现,体内缺乏铁元素,可引起T-淋巴细胞和B淋巴细胞生成受损,表现为数量和质量下降,吞噬细胞功能消弱,天然杀伤细胞数量减少等免疫功能降低的变化。而铁可使抗病能力的变化得以纠正恢复正常,达到抗感冒抗病的目的。
3、促进生长发育:处于快速生长发育阶段的儿童、青少年,缺铁性贫血发病率较高,但大多数是轻度的,没有明显的症状,常常被忽视。铁与红细胞内的血红蛋白的生成和成熟有关。血红蛋白有携代氧气的能力,通过血液循环,血红蛋白将氧输送到需氧的组织,保证组织内细胞的正常生长的代谢。由于铁缺乏将导致红细胞内血红蛋白的含量减少,携氧能力降低,从而影响儿童的正常生长发育。对于快速生长发育的儿童,由于自身血容量不断扩增,大量的红细胞合成需要大量的铁元素,很容易出现缺铁贫血。据有关调查,对于存在不同程度缺铁性贫血症状儿童比正常儿童身材低。
4、防治贫血:缺铁的症状主要是贫血,严重影响血液红细胞的数量低于正常值。人体各个器官组织缺氧—皮肤黏膜苍白、易疲劳、头晕气短、严重者工作和劳动能力下降、抗病能力低下。对儿童患有贫血的生长发育迟缓,学习能力降低。孕妇贫血不仅影响自身的健康,还影响胎儿生长发育不良及出生后贫血。老年贫血可导致认识反应能力衰退,精神处于抑郁症状,从而加速衰老进程。而铁是造血的营养素,它的主要功能是与蛋白质结合形成血红蛋白、血清铁、血清铁蛋白、进而形成血液中红细胞,因而可防治贫血。
5、抗疲劳:缺铁可引发疲劳,可导致大脑氧的红细胞减少,结果造成大脑缺乏能量,因而出现疲劳。铁作为机体多种重要酶的活性成分,人体是依靠O2氧化有机营养物以获得能量,释放能量的过程是在电子传递系统参与下完成的。经过初步代谢加工营养成分,在线粒体内膜上把电子传递给电子系统,然后初步传给O2使其变成水。铁还参与构成某些金属酶或激活某些金属酶的辅助因子,在体内运送氧和细胞内电子传递中的发挥作用。
6、提高记忆力:铁是红细胞中血红蛋白的重要成分。而脑的正常生理活动既需血液提供氧气,又需脑组织细胞中整套生物氧化酶进行催化。许多生物氧化酶属含铁蛋白质,它们对缺铁极为敏感。因耐缺铁儿童,往往智力低下、注意力不集中、记忆力差、表情淡漠等表现,缺铁纠正后,智力可随之恢复。另据报道,铁缺乏会影响蛋白质水解升高,抑制半乳糖脑苷脂的表达,导致神经系统髓鞘化不足,神经元的信号传导受阻。早期缺铁贫血的儿童长期影响可持续多年,在贫血儿童和对照受试者之中,他们的学习表现、感觉、运动能力、注意力、学习和记忆力存在很大差异。美国密歇根大学研究人员对185名儿童进行跟踪调查发现,婴幼儿严重缺铁的儿童,在学习能力、记忆能力和思考能力测试中都没有达到正常水平。
7、驱铅:据报道,美国加州大学研究发现,缺铁儿童血液中铅浓度比正常儿童高,表明缺铁儿童对家庭或周围环境中的铅有较高的敏感性,更容易发生铅蓄积甚至铅中毒。研究人员检测了300多名1-5岁的儿童血液中铁和铅的含量,并调查环境中的铅暴露情况,结果发现,越是在环境中铅含量高的地区,缺铁儿童和正常儿童血液中的铅浓度差异越大,提示缺铁会影响儿童对铅的代谢,导致铅蓄积。
(十一)锌(Zn)锌是人类机体必需的微量元素之一,是具有重要生理功能的营养素。锌在人体内的含量仅次于铁,机体含量为2-2.5克,正常血浆浓度为12-20umol/L,血浆中锌大多与蛋白质结合。锌主要存在于骨骼、牙齿、皮肤、神经、肌肉等器官中,尤其以视网膜、脉络膜、前列腺为量高。锌涉及生物体新陈代谢的各个方面,包括遗传物质的转录和复制;与人体的健康和疾病密切相关。锌是人体内100多种酶的辅助因子。其主要生物学作用有维持生物膜正常结构及功能;参与核酸及蛋白质代谢,与基因表达有关,参与酶的构成与激活激素的合成与分泌,影响激素与其受体的结合;并且与胸腺素及细胞因子有关。所以锌被人们誉为“生命之花”。
生理功能:1、促进生长发育:锌对儿童生长发育密切相关。因为锌与人体150多种酶及生长激素、核酸蛋白质的合成有关,而且对细胞的分裂、生长与再生,同时还能改善食欲及消化功能。因此,锌对处于生长发育旺盛期的儿童、青少年至关重要。另据报道,锌在骨骼发育代谢中有着重要的意义;锌可促进细胞增殖分化,使DNA、蛋白质合成增加,由此可见锌在骨生长中起着重要的作用。低锌会造成骨赂中心出现发育迟缓、骨质变薄、骨密度减少、骨外形表现为维生素D3缺乏所致骨钙化障碍相似。生长变薄变宽,仅有微弱的暂时性钙化,骨钙含量减少。
2、增强记忆力:锌的含量高低与学习记忆呈明显的正相关。锌主要结合在脑细胞膜上,能激活磷酸吡哆醛合成酶和抑制性Y-氨基丁酸(CGABA)合成酶,从而减少,抑制中枢神经递质Y-氨基丁酸的合成,锌在调节神经元Y-氨基丁酸浓度发挥关键作用。特别是人脑海马区锌浓度较高,而海马区是学习记忆的重要核团,因此,缺锌后影响脑海马区的正常代谢,从而影响学习记忆。美国一所大学研究发现,聪明学习好儿童青少年体内含锌量均比愚钝者高。另有报道,锌是人体200多种酶的组成部分,它参与核酸蛋白质的合成,细胞的分化与增殖,以及许多重要代谢。研究发现,人类大脑的海马区其重量约占整个大脑重量1/80左右,而其中的锌含量为大脑总含锌量的1/6。海马区是人类的高级神经活动的核团,是学习记忆,提高和存储信息逻辑部件,如海马区含锌量不足老年时会现出记忆减退、四肢活动障碍、思维功能异常,甚至会出现早老性痴呆。
3、增加免疫功能:适量补锌对保护机体免疫系统的完整性是极为重要的,它直接参与细胞免疫和体液免疫的过程。锌缺乏可使核酸合成中的RNA聚合酶和DNA聚合酶活性降低,影响细胞DNA的复制,造成淋巴细胞对各种抗原的增殖反应降低。锌还能诱导B淋巴细胞产生抗体。缺锌可使胸腺萎缩、胸腺素分泌减少、脾的重量减轻、T细胞数量减少、抗体产量下降、中性粒细胞趋化受抑制,从而导致机体抵抗力下降,免疫功能减退。补充适量的锌可改善单核细胞合成免疫因子的功能。儿童缺锌表现为淋巴细胞减少、胸腺萎缩、迟发过敏反应能力减弱、伤口愈合延缓、对病原微生物易感性增高。有关研究指出,在感冒发生时,适量补充锌可缩短病程,促进机体恢复。
4、防治近视:锌能增强视神经敏感度,改善屈光度防治近视。缺锌会影响维生素A在体内吸收,参与肝脏视网视素质的合成会产生障碍,从而影响锥状体、细胞的变色功能,因而补充维生素A的同时还应补充锌。锌在人的视觉神经中含量很高,有人对某中学的86名近视眼学生进行检测,发现他们血清中的锌含量均低于视力正常的对照组的人。因此,锌具有防治近视的功能。
5、保护味觉:锌元素对人体的味觉有良好的保护作用,可使你的食欲旺盛。因为锌对于味觉触头运作中出现的一种能够感知各种味觉的分子有影响。
此外,锌还具降血糖、抗肿瘤等功能。
综上所述:该产品以天然药食两用植物枸杞子、大枣、龙眼肉、山楂、沙棘、菊粉为主要原料,强化了牛黄酸、L-茶氨酸、钙、铁、锌等原料制成的儿童营养饮料。该产品营养素全面,味道好,健脾胃、促消化、补气养血,而且具有提高免疫力、促进儿童生长和大脑发育、增强记忆力、改善睡眠、调节肠道微生态、预防龋齿等功能。是处在生长发育期的少年儿童最佳的饮料。
六、制作工艺:
1、原料混合粉碎:先将配方中的植物原料混合粉碎为粗粉末。
2、浸提滤液:一次浸提原料水重量比为(1∶6-10)浸泡2小时,煮沸浸提1-3小时过滤得滤液一、二次滤渣加入(1∶6-8)水煮沸浸提1-2小时过滤得滤液二,两次滤液混合得原料提取液。
3、调配混合:将配方中强化原料与植物提取液混合溶化,充分搅拌均匀。
4、过滤:将搅拌均匀的提取液送入过滤机过滤。
5、灌装封盖:将过滤后的提取液送入灌装机灌装并封盖。
6、杀菌:将灌装封盖的饮料,加入80-100℃水中杀菌20分钟。
7、检验包装:将杀菌的饮料,检验合格,包装成为正式产品。
原料混合粉碎是为了提取原料中的所有化学成分的过程。浸提工序是在混合原料中加入适量水浸提原料成分的过程。调配混合工序是将配方中强化的原料溶化与植物提取液中,充分搅拌均匀的过程。过滤工序是为了过滤提取液中杂质的过程。灌装工序是把过滤的滤液送入灌装机灌入瓶中并封盖的过程。杀菌是为了杀死饮料中对人体有害的微生物和其它有害成分,延长货架期的过程。检验包装工序是对产品检验合格,包装成为正式产品。
七、质量标准:
1、理化指标:
2、适用人群:适用于男女青少年儿童。
八、具体实施方式
实施例:取枸杞子5千克,大枣6千克,龙眼肉3千克,山楂5千克,沙棘6千克,混合粉碎为粗粉末,加入(1∶8)水浸泡2小时,煮沸浸提2小时,过滤得滤液一,滤渣加入(1∶6)的水煮沸浸提1.5小时得滤液二,两次滤液混合加入强化原料溶化,搅拌均匀,送入灌装机灌装并封盖,在90℃水中杀菌20分钟,检验合格包装成为正式产品。
Claims (2)
1.儿童营养饮料制作工艺为:原料混合粉碎、二次水浸提、两次滤液混合加入强化原料溶化、搅拌过滤、灌装封盖、杀菌、检验包装成为正式产品。
2.工艺条件为:枸杞子5千克、大枣6千克、龙眼肉3千克、山楂5千克、沙棘6千克、菊粉2千克、牛黄酸0.3千克、L-茶氨酸0.2千克、乳酸钙4千克、乳酸亚铁0.18千克、葡萄糖酸锌0.2千克、辅料,先将原料中的植物原料混合粉碎为粗粉末,加入(1∶8)的水浸泡2小时,煮沸浸提2小时过滤得滤液一,滤渣加入(1∶6)的水煮沸浸提1.5小时过滤得滤液二,二次滤液混合加入强化原料溶化,搅拌均匀过滤,送入灌装机灌装并封盖,在90℃的水中杀菌20分钟,检验合格包装成为正式产品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011100492178A CN102160664A (zh) | 2011-02-21 | 2011-02-21 | 儿童营养饮料 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011100492178A CN102160664A (zh) | 2011-02-21 | 2011-02-21 | 儿童营养饮料 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102160664A true CN102160664A (zh) | 2011-08-24 |
Family
ID=44462329
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011100492178A Pending CN102160664A (zh) | 2011-02-21 | 2011-02-21 | 儿童营养饮料 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102160664A (zh) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102362994A (zh) * | 2011-11-02 | 2012-02-29 | 杨立君 | 健脾胃葡萄糖酸锌口服液 |
CN102389540A (zh) * | 2011-11-02 | 2012-03-28 | 杨立君 | 健脾胃葡萄糖酸钙口服液 |
CN102511623A (zh) * | 2011-12-28 | 2012-06-27 | 贵州神奇集团控股有限公司 | 一种含菊粉的养生枣及其制备方法 |
CN103190499A (zh) * | 2013-01-11 | 2013-07-10 | 李文雅 | 一种复合茶饮料及其制备方法 |
CN103652934A (zh) * | 2012-09-20 | 2014-03-26 | 江西钰鑫健康实业有限公司 | 用于增强婴幼儿免疫力营养因子食品补充剂的制备方法 |
CN104206955A (zh) * | 2014-08-17 | 2014-12-17 | 苟春虎 | 降血脂黑枸杞片 |
CN104231099A (zh) * | 2014-09-03 | 2014-12-24 | 佐源集团有限公司 | 一种菊粉锌及含有菊粉锌的口服液 |
CN104585833A (zh) * | 2015-02-15 | 2015-05-06 | 重庆骄王天然产物股份有限公司 | 一种菊粉沙棘果粉混合固体饮料 |
CN104738628A (zh) * | 2015-04-10 | 2015-07-01 | 吴春生 | 一种健脾养胃粉及其制备方法 |
CN104231099B (zh) * | 2014-09-03 | 2017-01-04 | 佐源集团有限公司 | 一种菊粉锌及含有菊粉锌的口服液 |
CN110179029A (zh) * | 2019-07-03 | 2019-08-30 | 刁杰 | 多维氨基酸植物饮品配方 |
-
2011
- 2011-02-21 CN CN2011100492178A patent/CN102160664A/zh active Pending
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102362994A (zh) * | 2011-11-02 | 2012-02-29 | 杨立君 | 健脾胃葡萄糖酸锌口服液 |
CN102389540A (zh) * | 2011-11-02 | 2012-03-28 | 杨立君 | 健脾胃葡萄糖酸钙口服液 |
CN102362994B (zh) * | 2011-11-02 | 2013-04-10 | 杨立君 | 健脾胃葡萄糖酸锌口服液 |
CN102511623A (zh) * | 2011-12-28 | 2012-06-27 | 贵州神奇集团控股有限公司 | 一种含菊粉的养生枣及其制备方法 |
CN102511623B (zh) * | 2011-12-28 | 2015-06-10 | 贵州神奇集团控股有限公司 | 一种含菊粉的养生枣及其制备方法 |
CN103652934A (zh) * | 2012-09-20 | 2014-03-26 | 江西钰鑫健康实业有限公司 | 用于增强婴幼儿免疫力营养因子食品补充剂的制备方法 |
CN103190499B (zh) * | 2013-01-11 | 2014-08-06 | 李文雅 | 一种复合茶饮料及其制备方法 |
CN103190499A (zh) * | 2013-01-11 | 2013-07-10 | 李文雅 | 一种复合茶饮料及其制备方法 |
CN104206955A (zh) * | 2014-08-17 | 2014-12-17 | 苟春虎 | 降血脂黑枸杞片 |
CN104231099A (zh) * | 2014-09-03 | 2014-12-24 | 佐源集团有限公司 | 一种菊粉锌及含有菊粉锌的口服液 |
CN104231099B (zh) * | 2014-09-03 | 2017-01-04 | 佐源集团有限公司 | 一种菊粉锌及含有菊粉锌的口服液 |
CN104585833A (zh) * | 2015-02-15 | 2015-05-06 | 重庆骄王天然产物股份有限公司 | 一种菊粉沙棘果粉混合固体饮料 |
CN104738628A (zh) * | 2015-04-10 | 2015-07-01 | 吴春生 | 一种健脾养胃粉及其制备方法 |
CN110179029A (zh) * | 2019-07-03 | 2019-08-30 | 刁杰 | 多维氨基酸植物饮品配方 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102160664A (zh) | 儿童营养饮料 | |
CN102293430B (zh) | 一种具有抗氧化、增强免疫力的饮料及其制备方法 | |
MXPA06012501A (es) | Composicion nutricional que promueve la perdida de peso, quema calorias, aumenta la termogenesis, sustenta el metabolismo de la energia y/o suprime el apetito. | |
CN1625406A (zh) | 用于预防和治疗温血动物的应激状态的含有溶血磷脂酰丝氨酸的制剂 | |
CN102526698A (zh) | 虫草多肽氨基酸营养液 | |
CN101926459A (zh) | 一种能提升学习记忆力预防考试焦虑的制剂及制备方法 | |
CN103859379A (zh) | 一种有助于改善记忆的养生保健食品配方及其制备方法 | |
CN103190483A (zh) | 儿童成长奶茶 | |
CN101637265A (zh) | 一种用于改善睡眠的保健食品 | |
CN101396115A (zh) | 一种低聚木糖健胃润肠口服液及其制备方法 | |
US20080286388A1 (en) | Pharmaceutical Composition and Non Dependence Coffee Comprising Edible Carboxylic Acid and/or Its Acid Salts and Coffeine | |
JP2014237715A (ja) | アルコール性疲労改善剤 | |
CN114916631A (zh) | 一种超高纯度二十八烷醇-黄酮复合去氘水组合协同精制的高能饮料及其制备方法 | |
CN107007646A (zh) | 一种辅助防治癌症的营养复合物 | |
KR101642176B1 (ko) | 성장촉진 조성물 | |
CN103238889A (zh) | 一种抗疲劳苹果醋保健饮料及其制备方法 | |
CN105029553A (zh) | 一种果汁蛋钙中药保健饮料及其制备方法 | |
CN102119939B (zh) | 用于治疗脂肪肝的被子植物蜂花粉水提取物及其制备方法、用途 | |
CN108771246B (zh) | 提高术后或化疗后患者的免疫力和恢复生理机能的组合物 | |
CN113349380A (zh) | 一种含牡蛎复合肽肾功能改善剂及其制备方法 | |
CN104222286A (zh) | 改善智力的保健牛奶及其制备方法 | |
CN107439866A (zh) | 枸杞鹰嘴豆植物营养素饮料及其制备工艺 | |
WO2005087022A1 (ja) | 抗ストレス作用を有する食品組成物 | |
WO2022169973A1 (en) | Dietary supplement for improving brain performance | |
CN106819223A (zh) | 一种保健奶茶及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20110824 |